Protalix BioTherapeutics, Inc. PLX
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Protalix BioTherapeutics, Inc. (PLX) is a healthcare company listed in the US with a market value of about $257M. In the twelve months to September 30, 2026 it had revenue of $85M and net income of $21M, a net margin of 24.3%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is track record (0/5).
Key numbers: a P/E of 12.2, a price to free cash flow of 17.1, 5-year revenue growth of -3% a year, a 5-year average ROIC of -16%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 92% below the current price.
About Protalix BioTherapeutics
Protalix BioTherapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $9M in 2014 to $53M in 2025, growth of about 17.3% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 62% over three years (dilution for shareholders). It spends 37% of revenue on research and development.
Score: 1.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85M | $53M | $53M | $65M | $48M | $38M | $63M | $55M | $34M | $21M | $9M |
| Net income | $21M | -$7M | $3M | $8M | -$15M | -$28M | -$7M | -$18M | -$26M | -$83M | -$29M |
| Free cash flow | $15M | -$14M | $7M | -$2M | -$26M | -$12M | -$27M | -$20M | -$8M | -$11M | -$33M |
| EPS (diluted) | $0.25 | $-0.08 | $0.04 | $0.09 | $-0.31 | $-0.62 | $-0.22 | $-1.23 | $-1.80 | $-6.37 | $-2.90 |
| Net margin | 24.3% | -12.5% | 5.5% | 12.7% | -31.3% | -71.9% | -10.4% | -33.4% | -77.3% | -395.9% | -319.2% |
| ROIC | — | -7.7% | 5.7% | 25.6% | -45.0% | -58.9% | — | — | -1943.1% | -162.2% | -279.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $12.00, 293% above the current price; targets range from $12.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $0.28 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Protalix BioTherapeutics’s P/E ratio?
About 12.2, based on the last twelve months of diluted earnings per share (forward P/E about 10.9).
Is Protalix BioTherapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 92% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Protalix BioTherapeutics pay a dividend?
Not currently.
Is Protalix BioTherapeutics a good stock to buy?
We do not give buy or sell advice. Protalix BioTherapeutics scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.